• July 31, 2025

  Revenue of LEQEMBI® (Preliminary Basis)

• July 31, 2025

  Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
  Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease
  
  56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years

• July 31, 2025

  New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
  Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation

• July 31, 2025

  Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

• July 29, 2025

  LENVIMA® (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma

View All

• August 5, 2025

  IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2026 (Audio)”

• August 5, 2025

  IR “First Quarter Financial Reports for the Fiscal Year Ending March 31, 2026”

• June 19, 2025

  About Eisai “Corporate Governance Report”

• May 21, 2025

  Sustainability “Call for Support of Japanese Corporate Activities and ODA in the Global Health Sector ー Letter of Request Delivered to Mr. Takamaro Fukuoka, Minister of Health, Labour and Welfare”

• May 16, 2025

  IR “Notice of Convocation of the 113th Ordinary General Meeting of Shareholders”

View All

• February 19, 2025

  Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”

• October 3, 2024

  EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024

• June 21, 2024

  Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”

• June 3, 2024

  The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”

• April 8, 2024

  Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant

View All